• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Mineralys Therapeutics Inc.

    11/13/24 4:09:56 PM ET
    $MLYS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MLYS alert in real time by email
    SC 13G/A 1 d847797dsc13ga.htm SC 13G/A SC 13G/A

     

     

    Securities and Exchange Commission

    Washington, D.C. 20549

     

     

    Schedule 13G

    (Rule 13d-102)

    Information to be Included in Statements Filed Pursuant

    to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed

    Pursuant to § 240.13d-2

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

    (Amendment No. 1)*

     

     

    Mineralys Therapeutics, Inc.

    (Name of Issuer)

    Common Stock

    (Title of Class of Securities)

    603170101

    (CUSIP Number)

    September 30, 2024

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ☐

    Rule 13d-1(b)

     

    ☐

    Rule 13d-1(c)

     

    ☒

    Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. 603170101   Schedule 13G   Page 1 of 9

     

     1   

     Names of Reporting Persons

     

     Catalys Pacific Fund, LP

     2  

     Check the Appropriate Box if a Member of a Group

     (a) ☐  (b) ☐

     

     3  

     SEC Use Only

     

     4  

     Citizenship or Place of Organization

     

     Cayman Islands

    Number of

    Shares  Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

       5   

     Sole Voting Power

     

     0

       6  

     Shared Voting Power

     

     8,681,245

       7  

     Sole Dispositive Power

     

     0

       8  

     Shared Dispositive Power

     

     8,681,245

     9   

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     8,681,245

    10  

     Check if the Aggregate Amount in Row (9) Excludes Certain Shares

     

     Not Applicable

    11  

     Percent of Class Represented by Amount in Row 9

     

     17.4%

    12  

     Type of Reporting Person

     

     PN


    CUSIP No. 603170101   Schedule 13G   Page 2 of 9

     

     1   

     Names of Reporting Persons

     

     Catalys Pacific Fund GP, LP

     2  

     Check the Appropriate Box if a Member of a Group

     (a) ☐  (b) ☐

     

     3  

     SEC Use Only

     

     4  

     Citizenship or Place of Organization

     

     Cayman Islands

    Number of

    Shares  Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

       5   

     Sole Voting Power

     

     0

       6  

     Shared Voting Power

     

     8,681,245

       7  

     Sole Dispositive Power

     

     0

       8  

     Shared Dispositive Power

     

     8,681,245

     9   

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     8,681,245

    10  

     Check if the Aggregate Amount in Row (9) Excludes Certain Shares

     

     Not Applicable

    11  

     Percent of Class Represented by Amount in Row 9

     

     17.4%

    12  

     Type of Reporting Person

     

     PN


    CUSIP No. 603170101   Schedule 13G   Page 3 of 9

     

     1   

     Names of Reporting Persons

     

     Catalys Pacific, LLC

     2  

     Check the Appropriate Box if a Member of a Group

     (a) ☐  (b) ☐

     

     3  

     SEC Use Only

     

     4  

     Citizenship or Place of Organization

     

     Cayman Islands

    Number of

    Shares  Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

       5   

     Sole Voting Power

     

     0

       6  

     Shared Voting Power

     

     8,681,245

       7  

     Sole Dispositive Power

     

     0

       8  

     Shared Dispositive Power

     

     8,681,245

     9   

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     8,681,245

    10  

     Check if the Aggregate Amount in Row (9) Excludes Certain Shares

     

     Not Applicable

    11  

     Percent of Class Represented by Amount in Row 9

     

     17.4%

    12  

     Type of Reporting Person

     

     OO


    CUSIP No. 603170101   Schedule 13G   Page 4 of 9

     

     1   

     Names of Reporting Persons

     

     Brian Taylor Slingsby

     2  

     Check the Appropriate Box if a Member of a Group

     (a) ☐  (b) ☐

     

     3  

     SEC Use Only

     

     4  

     Citizenship or Place of Organization

     

     United States of America

    Number of

    Shares  Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

       5   

     Sole Voting Power

     

     0

       6  

     Shared Voting Power

     

     8,681,245

       7  

     Sole Dispositive Power

     

     0

       8  

     Shared Dispositive Power

     

     8,681,245

     9   

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     8,681,245

    10  

     Check if the Aggregate Amount in Row (9) Excludes Certain Shares

     

     Not Applicable

    11  

     Percent of Class Represented by Amount in Row 9

     

     17.4%

    12  

     Type of Reporting Person

     

     IN


    CUSIP No. 603170101   Schedule 13G   Page 5 of 9

     

    ITEM 1.     (a)    Name of Issuer:
         

    Mineralys Therapeutics, Inc. (the “Issuer”).

       (b)    Address of Issuer’s Principal Executive Offices:
         

    150 N. Radnor Chester Rd, Suite F200, Radnor, PA 19087

    ITEM 2.    (a)    Name of Person Filing:
         

    Each of the following is hereinafter individually referred to as a “Reporting Person” and collectively as the “Reporting Persons.” This statement is filed on behalf of:

         

    Catalys Pacific Fund, LP

         

    Catalys Pacific Fund GP, LP

         

    Catalys Pacific, LLC

         

    Brian Taylor Slingsby

       (b)    Address or Principal Business Office:
         

    The principal business address for Catalys Pacific Fund, LP, Catalys Pacific Fund GP, LP and Catalys Pacific, LLC is PO Box 309, Ugland House, Grand Cayman, KY1-1104, Cayman Islands.

         

    The principal business address for Brian Taylor Slingsby is 1516 Bigelow Ave N, Seattle, WA 98109.

       (c)    Citizenship of each Reporting Person is:
         

    Brian Taylor Slingsby is a citizen of the United States. The other Reporting Persons are each entities organized under the laws of the Cayman Islands.

       (d)    Title of Class of Securities:
         

    Common Stock, par value $0.0001 per share (“Common Stock”).

       (e)    CUSIP Number:
         

    603170101

    ITEM 3.      

    Not applicable.


    CUSIP No. 603170101   Schedule 13G   Page 6 of 9

     

    ITEM 4.     Ownership.
       (a-c)
      

    The ownership information presented below represents beneficial ownership of Common Stock of the Issuer as of September 30, 2024, based upon 49,726,675 shares of Common Stock outstanding as of August 2, 2024, as disclosed in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 13, 2024.

     

    Reporting Person   

    Amount

    beneficially

    owned

        

    Percent

    of class:

        Sole power
    to vote or
    to direct
    the vote:
         Shared
    power to
    vote or to
    direct the
    vote:
        

    Sole
    power to
    dispose or
    to direct
    the
    disposition

    of:

        

    Shared

    power to

    dispose or

    to direct

    the

    disposition

    of:

     

    Catalys Pacific Fund, LP

         8,681,245        17.4 %      0        8,681,245        0        8,681,245  

    Catalys Pacific Fund GP, LP

         8,681,245        17.4 %      0        8,681,245        0        8,681,245  

    Catalys Pacific, LLC

         8,681,245        17.4 %      0        8,681,245        0        8,681,245  

    Brian Taylor Slingsby

         8,681,245        17.4 %      0        8,681,245        0        8,681,245  

    Catalys Pacific Fund, LP is the beneficial owner of 8,681,245 shares of Common Stock, which includes 8,644,579 shares of Common Stock held of record by Catalys Pacific Fund, LP and 36,666 shares of Common Stock underlying stock options that are exercisable within 60 days of September 30, 2024.

    Catalys Pacific Fund GP, LP is the general partner of Catalys Pacific Fund, LP. Catalys Pacific, LLC is the general partner of Catalys Pacific Fund GP, LP. Brian Taylor Slingsby is the managing director of Catalys Pacific, LLC. As a result, each of the Reporting Persons may be deemed to share beneficial ownership over the securities reported herein.

     

    ITEM 5.

    Ownership of Five Percent or Less of a Class.

    Not applicable.

     

    ITEM 6.

    Ownership of More than Five Percent on Behalf of Another Person.

    Not applicable.

     

    ITEM 7.

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

    Not applicable.

     

    ITEM 8.

    Identification and Classification of Members of the Group.

    Not applicable.


    CUSIP No. 603170101   Schedule 13G   Page 7 of 9

     

    ITEM 9.

    Notice of Dissolution of Group.

    Not applicable.

     

    ITEM 10.

    Certification.

    Not applicable.


    CUSIP No. 603170101   Schedule 13G   Page 8 of 9

     

    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date: November 13, 2024

     

    Catalys Pacific Fund, LP
    By:   Catalys Pacific Fund GP, LP, its General Partner
    By:   Catalys Pacific, LLC, its General Partner
    By:  

    /s/ Brian Taylor Slingsby

    Name:   Brian Taylor Slingsby
    Title:   Managing Director
    Catalys Pacific Fund GP, LP
    By:   Catalys Pacific, LLC, its General Partner
    By:  

    /s/ Brian Taylor Slingsby

    Name:   Brian Taylor Slingsby
    Title:   Managing Director
    Catalys Pacific, LLC
    By:  

    /s/ Brian Taylor Slingsby

    Name:   Brian Taylor Slingsby
    Title:   Managing Director

    /s/ Brian Taylor Slingsby


    CUSIP No. 603170101   Schedule 13G   Page 9 of 9

     

    LIST OF EXHIBITS

     

    Exhibit No.

      

    Description

    99    Joint Filing Agreement (previously filed).
    Get the next $MLYS alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MLYS

    DatePrice TargetRatingAnalyst
    6/11/2025$15.00Hold
    Jefferies
    7/10/2024$30.00Buy
    H.C. Wainwright
    4/2/2024$30.00Buy
    Goldman
    3/7/2023Outperform
    Evercore ISI
    3/7/2023$39.00Buy
    BofA Securities
    3/7/2023$32.00Buy
    Guggenheim
    3/7/2023$27.00Overweight
    Wells Fargo
    3/7/2023$45.00Buy
    Stifel
    More analyst ratings

    $MLYS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Jefferies initiated coverage on Mineralys Therapeutics with a new price target

    Jefferies initiated coverage of Mineralys Therapeutics with a rating of Hold and set a new price target of $15.00

    6/11/25 7:54:20 AM ET
    $MLYS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    H.C. Wainwright initiated coverage on Mineralys Therapeutics with a new price target

    H.C. Wainwright initiated coverage of Mineralys Therapeutics with a rating of Buy and set a new price target of $30.00

    7/10/24 7:50:59 AM ET
    $MLYS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Goldman initiated coverage on Mineralys Therapeutics with a new price target

    Goldman initiated coverage of Mineralys Therapeutics with a rating of Buy and set a new price target of $30.00

    4/2/24 7:34:24 AM ET
    $MLYS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MLYS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Mineralys Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

    – Presented and published the positive results from both the Launch-HTN and Advance-HTN pivotal trials at scientific meetings and in JAMA and NEJM – – Pre-NDA meeting scheduled to take place in 4Q 2025 – – Explore-CKD Phase 2 trial successfully achieved statistical significance in reduction of systolic BP and UACR, and demonstrated a favorable safety profile – – Explore-OSA Phase 2 trial in OSA participants with hypertension is ongoing; topline results anticipated in 1H 2026 – – Conference call today at 4:30 p.m. ET – RADNOR, Pa., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ:MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to

    8/12/25 4:05:00 PM ET
    $MLYS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Mineralys Therapeutics to Announce Second Quarter 2025 Financial Results and Host Conference Call on Tuesday, August 12, 2025

    RADNOR, Pa., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ:MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as hypertensive nephropathy, obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, today announced it will report its financial results from the second quarter ended June 30, 2025, after the financial markets close on Tuesday, August 12, 2025. Tuesday, August 12th @ 4:30 p.m. ETDomestic:1-877-704-4453International:1-201-389-0920Conference ID:13754684Webcast:Webcast Link   A live webcast of the conference call may also be found on the "News & E

    8/4/25 4:05:00 PM ET
    $MLYS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Mineralys Therapeutics Announces Positive Topline Results from Phase 2 Explore-CKD Trial of Lorundrostat for the Treatment of Hypertension in Subjects with CKD and Albuminuria

    – Explore-CKD met its primary endpoint; lorundrostat 25 mg once daily achieved a 9.3 mmHg reduction in systolic blood pressure, and a 7.5 mmHg placebo-adjusted reduction (p=0.0024) at four weeks – – Lorundrostat showed a clinically meaningful reduction in the pre-defined endpoint spot urine albumin-to-creatinine ratio of 31% (p<0.0001) – – Lorundrostat demonstrated a favorable safety and tolerability profile – – Conference call today at 8:00 a.m. ET – RADNOR, Pa., June 17, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ:MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD), obstructive sleep

    6/17/25 7:00:00 AM ET
    $MLYS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MLYS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Slingsby Brian Taylor bought $3,499,996 worth of shares (259,259 units at $13.50) (SEC Form 4)

    4 - Mineralys Therapeutics, Inc. (0001933414) (Issuer)

    4/25/25 7:01:59 PM ET
    $MLYS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Samsara Biocapital Gp, Llc bought $8,100,000 worth of shares (600,000 units at $13.50) (SEC Form 4)

    4 - Mineralys Therapeutics, Inc. (0001933414) (Issuer)

    3/17/25 9:05:47 PM ET
    $MLYS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Akkaraju Srinivas bought $8,100,000 worth of shares (600,000 units at $13.50) (SEC Form 4)

    4 - Mineralys Therapeutics, Inc. (0001933414) (Issuer)

    3/17/25 9:04:15 PM ET
    $MLYS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MLYS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Medical Officer Rodman David Malcom exercised 6,349 shares at a strike of $1.08 and sold $146,987 worth of shares (11,365 units at $12.93), decreasing direct ownership by 5% to 92,891 units (SEC Form 4)

    4 - Mineralys Therapeutics, Inc. (0001933414) (Issuer)

    8/14/25 6:02:58 PM ET
    $MLYS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CFO and Secretary Levy Adam Scott sold $1,077,477 worth of shares (73,678 units at $14.62), decreasing direct ownership by 36% to 132,934 units (SEC Form 4)

    4 - Mineralys Therapeutics, Inc. (0001933414) (Issuer)

    7/30/25 8:12:01 PM ET
    $MLYS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Congleton Jon sold $230,431 worth of shares (15,884 units at $14.51), decreasing direct ownership by 2% to 846,405 units (SEC Form 4)

    4 - Mineralys Therapeutics, Inc. (0001933414) (Issuer)

    7/15/25 5:02:38 PM ET
    $MLYS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MLYS
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Mineralys Therapeutics Inc.

    SCHEDULE 13G/A - Mineralys Therapeutics, Inc. (0001933414) (Subject)

    8/14/25 4:13:57 PM ET
    $MLYS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Mineralys Therapeutics Inc.

    SCHEDULE 13G/A - Mineralys Therapeutics, Inc. (0001933414) (Subject)

    8/14/25 4:05:09 PM ET
    $MLYS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by Mineralys Therapeutics Inc.

    144 - Mineralys Therapeutics, Inc. (0001933414) (Subject)

    8/13/25 5:21:54 PM ET
    $MLYS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MLYS
    Financials

    Live finance-specific insights

    View All

    Mineralys Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

    – Presented and published the positive results from both the Launch-HTN and Advance-HTN pivotal trials at scientific meetings and in JAMA and NEJM – – Pre-NDA meeting scheduled to take place in 4Q 2025 – – Explore-CKD Phase 2 trial successfully achieved statistical significance in reduction of systolic BP and UACR, and demonstrated a favorable safety profile – – Explore-OSA Phase 2 trial in OSA participants with hypertension is ongoing; topline results anticipated in 1H 2026 – – Conference call today at 4:30 p.m. ET – RADNOR, Pa., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ:MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to

    8/12/25 4:05:00 PM ET
    $MLYS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Mineralys Therapeutics to Announce Second Quarter 2025 Financial Results and Host Conference Call on Tuesday, August 12, 2025

    RADNOR, Pa., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ:MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as hypertensive nephropathy, obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, today announced it will report its financial results from the second quarter ended June 30, 2025, after the financial markets close on Tuesday, August 12, 2025. Tuesday, August 12th @ 4:30 p.m. ETDomestic:1-877-704-4453International:1-201-389-0920Conference ID:13754684Webcast:Webcast Link   A live webcast of the conference call may also be found on the "News & E

    8/4/25 4:05:00 PM ET
    $MLYS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Mineralys Therapeutics Announces Positive Topline Results from Phase 2 Explore-CKD Trial of Lorundrostat for the Treatment of Hypertension in Subjects with CKD and Albuminuria

    – Explore-CKD met its primary endpoint; lorundrostat 25 mg once daily achieved a 9.3 mmHg reduction in systolic blood pressure, and a 7.5 mmHg placebo-adjusted reduction (p=0.0024) at four weeks – – Lorundrostat showed a clinically meaningful reduction in the pre-defined endpoint spot urine albumin-to-creatinine ratio of 31% (p<0.0001) – – Lorundrostat demonstrated a favorable safety and tolerability profile – – Conference call today at 8:00 a.m. ET – RADNOR, Pa., June 17, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ:MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD), obstructive sleep

    6/17/25 7:00:00 AM ET
    $MLYS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MLYS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Mineralys Therapeutics Inc.

    SC 13G/A - Mineralys Therapeutics, Inc. (0001933414) (Subject)

    11/13/24 4:27:48 PM ET
    $MLYS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Mineralys Therapeutics Inc.

    SC 13G/A - Mineralys Therapeutics, Inc. (0001933414) (Subject)

    11/13/24 4:19:46 PM ET
    $MLYS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Mineralys Therapeutics Inc.

    SC 13G/A - Mineralys Therapeutics, Inc. (0001933414) (Subject)

    11/13/24 4:09:56 PM ET
    $MLYS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MLYS
    Leadership Updates

    Live Leadership Updates

    View All

    Mineralys Therapeutics Appoints Minji Kim, Ph.D. as Chief Business Officer

    RADNOR, Pa., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ:MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by abnormally elevated aldosterone, today announced the appointment of Minji Kim, Ph.D. as Chief Business Officer. Adam Levy will remain in his role as Chief Financial Officer. "With our expanding operations, we have decided to split the functions of Chief Financial Officer and Chief Business Officer into two roles, and we are excited to have Minji join our team. She brings a solid track record of generating value for multiple companies by identify

    1/4/24 4:05:00 PM ET
    $MLYS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Praxis Bioresearch Expands its Board of Directors with Appointment of Adam Levy

    LOS ANGELES, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Praxis Bioresearch ("Praxis"), a biopharmaceutical company focused on the discovery and development of therapeutics for chronic neuropsychiatric and neurodegenerative disorders with an initial focus on apathy in Alzheimer's Disease, today announced the appointment of Adam Levy to its Board of Directors (the "Board"). Mr. Levy brings executive, financial and operational leadership experience in biopharmaceuticals. "We are excited to have Adam join our Board and support our mission to improve the lives of patients with Alzheimer's Disease," said Sandeep Patil, MD PhD, chief executive officer of Praxis Bioresearch. "Adam brings an impressive

    9/19/23 4:00:00 PM ET
    $MLYS
    Biotechnology: Pharmaceutical Preparations
    Health Care